Since osimertinib is designed to modulate EGFR activity, we next used the RPPA data to evaluate changes in EGFR expression across MCPs, the parental line, and the 14 NSCLC control lines with diverse genomic background. Here, EGFR is linked to non-small cell lung carcinoma.